All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Onasemnogene abeparvovec-xioi
Therapeutic Area: Musculoskeletal Product Name: Zolgensma
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Healthcare Royalty Management
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Agreement December 22, 2020
Details:
REGENXBIO will receive $200 million from HCR as an upfront payment in exchange for REGENXBIO's royalty rights from the net sales of Zolgensma. Agreement provides REGENXBIO with significant additional non-dilutive funding to advance RGX-314 and RGX-121.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Succinylcholine Chloride
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dantrolene Sodium
Therapeutic Area: Musculoskeletal Product Name: Ryanodex
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: JPMorgan Chase Bank
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Investment September 24, 2020
Details:
The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulvestrant and SM-88.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tolperisone
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The presentation will highlight results from a double-blind, randomized, placebo-controlled, multicenter phase 3 study evaluating Tolperisone 100 and 200 mg Three Times Daily (TID) for acute muscle spasm of the back.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
Antares development partner Teva, launched Teriparatide Injection (“teriparatide”), the generic version of Eli Lilly’s brand product Forsteo® featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary,
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Livogiva
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
Details:
Pfenex received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Succinylcholine Chloride
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
The U.S. FDA has approved Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL Multiple-Dose Vial. Amphastar’s drug product was determined by the FDA to be therapeutically equivalent to Succinylcholine Chloride Injection USP, 200 mg/10 mL.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
